article Open AccessTop 1% cited
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
Psychological Medicine · 2018 · Vol. 49(4) · pp. 655–663
Fernanda Palhano-Fontes(Hospital Universitário Onofre Lopes)Dayanna Barreto(Hospital Universitário Onofre Lopes)Heloisa Onias(Hospital Universitário Onofre Lopes)Kátia C. Andrade(Hospital Universitário Onofre Lopes)Morgana Menezes Novaes(Universidade Federal do Rio Grande do Norte)Jéssica Andrade Pessoa(Universidade Federal do Rio Grande do Norte)Sérgio Mota‐Rolim(Hospital Universitário Onofre Lopes)Flávia de Lima Osório(Instituto de Neurociências e Comportamento)Rafael Faria Sanches(Universidade de São Paulo)Rafael G. dos Santos(Universidade de São Paulo)Luís Fernando Tófoli(Universidade Estadual de Campinas (UNICAMP))Gabriela de Oliveira SilveiraMaurı́cio YonamineJordi Riba(Institut de Recerca Sant Pau)Francisco R. Santos(Universidade Federal do Rio Grande do Norte)Antonio A Silva-Junior(Universidade Federal do Rio Grande do Norte)João Carlos Alchieri(Universidade Federal do Rio Grande do Norte)Nicole Leite Galvão‐Coelho(Instituto de Neurociências e Comportamento)Bruno Lobão‐Soares(Instituto de Neurociências e Comportamento)Jaime E. C. Hallak(Universidade de São Paulo)Emerson Arcoverde(Hospital Universitário Onofre Lopes)João Paulo Maia‐de‐Oliveira(Instituto de Neurociências e Comportamento)Dráulio Barros de Araújo✉(Hospital Universitário Onofre Lopes)
Abstract
To our knowledge, this is the first controlled trial to test a psychedelic substance in treatment-resistant depression. Overall, this study brings new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression. This study is registered at http://clinicaltrials.gov (NCT02914769).
Psychedelics and Drug StudiesNeurotransmitter Receptor Influence on BehaviorTryptophan and brain disordersAyahuascaPlaceboDepression (economics)AntidepressantTreatment-resistant depressionRandomized controlled trialPsychologyInternal medicineRating scaleHallucinogen
MeSH terms
AdultAntidepressive AgentsDouble-Blind MethodFemaleHallucinogensHumansMalePhytotherapyPsychiatric Status Rating ScalesTime FactorsTreatment OutcomeBanisteriopsisDepressive Disorder, Treatment-Resistant
Funding
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Universidade Federal do Rio Grande do Norte
Citations
797
FWCI
70.62
field-weighted impact
References
54
Percentile
100%
vs. same field & year
Citations per year
References
Antidepressant effects of ketamine in depressed patients
Biological Psychiatry · 2000 · 3,787 citations
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Archives of General Psychiatry · 2006 · 3,706 citations
A RATING SCALE FOR DEPRESSION
Journal of Neurology Neurosurgery & Psychiatry · 1960 · 32,326 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.